Skip to main navigation
Intercept Pharmaceuticals homepage
  • News
Intercept Pharmaceuticals Logo
Menu
Close✕
  • About Us
    • Leadership
    • News
    • Company Statements
    • OCALIVA: Withdrawal Process
  • Our Focus
    • Meet Ally
    • Patient Resources
  • Our Research
    • FXR
    • Pipeline
    • Medical Information Request Form
  • Careers
    • Job Postings
  • Contact Us
  • Media
Home > Careers

An opportunity to
MAKE AN IMPACT

We’re a biopharmaceutical company working to make a difference in the lives of people with rare and serious liver diseases.

  • Careers
    • Job Postings
Intercept Pharmaceuticals, a wholly owned subsidiary of Alfasigma, is part of a rapidly expanding global biopharmaceutical leader with a presence in over 100 countries. Our mission is rooted in advancing innovative therapies for people living with serious liver diseases, and our team is dedicated to bringing hope to those whose health journeys demand new solutions.

co-workers conference room collaboration

If you thrive on curiosity, value diverse perspectives, embrace bold thinking, and are passionate about creating life-changing solutions, you belong here—where innovation drives everything we do.

Job Postings

View our available career opportunities.

See All
co-workers conference room collaboration


  • Our Focus
    • Meet Ally
    • Patient Resources
  • Our Research
    • FXR
    • Pipeline
    • Medical Information Request Form
  • About Us
    • Leadership >
    • News >
  • Careers
    • Job Postings
Intercept Pharmaceuticals Logo
  • Website Privacy Policy
  • Consumer Health Data Privacy Policy
  • EU-US Data Privacy Framework (DPF) Policy
  • Corporate Compliance
  • Terms of Use
  • Contact Us
  • Cookie Preferences
  • Transparency Disclosures
305 Madison Avenue |Morristown, NJ 07960|T: 1-844-782–4278
© 2024 Intercept Pharmaceuticals, Inc.
US-NP-OT-0023
US-NP-OT-0023

YOU ARE NOW leaving interceptpharma.com


You are now leaving Intercept Pharmaceuticals’ corporate website and entering a site intended for U.S. audiences only.

Continue

YOU ARE NOW leaving interceptpharma.com


You are now leaving Intercept Pharmaceuticals’ corporate website. Intercept does not control or endorse the content of this external site.

Continue

YOU ARE NOW leaving interceptpharma.com


You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Intercept provides this link as a service to its website visitors. Intercept is not responsible for the content or the privacy policy of any third party websites.

Close this window to return to Intercept Pharmaceuticals’ site or click ‘Continue’ to proceed.

Continue

United States (US)
European Union (EU)
Canada
Israel
Switzerland
Australia
Liechtenstein
United Arab Emirates (UAE)

Close

Exploring Racial Differences and Disparities in PBC Care

Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., has voluntarily withdrawn OCALIVA® (obeticholic acid) from the market for the treatment of primary biliary cholangitis (PBC), effective November 14.

Patients should talk to their healthcare professionals and may also contact Intercept's patient support services (Interconnect at 1-844-622-4278) through December 31, 2025.

Healthcare professionals can contact Medical Information at medinfo@interceptpharma.com or 1-844-782-4278. Additionally, patients or healthcare professionals may request Full Prescribing Information or the OCALIVA Medication Guide by contacting medinfo@interceptpharma.com.

For all other inquiries please contact: info@interceptpharma.com

Acknowledge